ClariVest Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

ClariVest Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-28,335	Closed	-$524K	–	846
2024 Q1	$524K	Buy	28,335 +31	+0.1%	+$768	0.05%	355
2023 Q4	$886K	Sell	28,304 -5,000	-15%	-$119K	0.05%	282
2023 Q3	$694K	Buy	+33,304	New	+$905K	0.04%	305
2021 Q1	–	Sell	-54,880	Closed	-$2.93M	–	733
2020 Q4	$2.93M	Sell	54,880 -400	-0.7%	-$19.9K	0.1%	171
2020 Q3	$2.28M	Sell	55,280 -1,190	-2%	-$51.4K	0.07%	204
2020 Q2	$2.74M	Sell	56,470 -64,581	-53%	-$3.1M	0.07%	188
2020 Q1	$5.11M	Sell	121,051 -3,319	-3%	-$137K	0.15%	104
2019 Q4	$5.32M	Sell	124,370 -38,196	-23%	-$1.66M	0.12%	140
2019 Q3	$5.85M	Buy	+162,566	New	+$4.93M	0.13%	152
2016 Q2	–	Sell	-36,254	Closed	-$1.01M	–	625
2016 Q1	$1.01M	Buy	+36,254	New	+$791K	0.03%	282

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ClariVest Asset Management's ACAD Position: Q2 2024 in Review

ClariVest Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 28,335 shares — an estimated $524K sold.

ClariVest Asset Management first reported a position in ACAD in Q1 2016 and held it in 10 quarters. The position peaked at $5.85M in Q3 2019. 265 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

ClariVest Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
ClariVest Asset Management sold 28,335 Acadia Pharmaceuticals shares in Q2 2024, an estimated $524K.
ClariVest Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 10 quarters.
ClariVest Asset Management's Acadia Pharmaceuticals position peaked at $5.85M in Q3 2019.
265 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on ClariVest Asset Management's 13F filing for Q2 2024, filed 7 Aug 2024.